Lion's Mane (Hericium erinaceus): A neurotrophic fungus of MCI, depression, and brain damage

Lion's Mane (Hericium erinaceus), also known as Lion's Mane or Japanese yamabushitake, is one of the most researched neurotrophic mushrooms in 21st-century pharmacology. By the end of the first quarter of 2026, there are over 620 publications in the PubMed database regarding this species, of which 38 are randomized clinical trials on humans. The uniqueness of Lion's Mane arises from the presence of two classes of neuroactive compounds not found in other medicinal mushrooms: hericenones and erinacines. Both significantly influence the synthesis of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF). This text discusses the taxonomy of the species, the chemistry of active compounds, mechanisms of action in the central nervous system, data from randomized clinical trials on patients with MCI, antidepressant potential, dosing, forms of preparations, and safety profile.

an article on the classification of adaptogens and the HPA axis

What is Lion's Mane and what is its place in the taxonomy of fungi?

Lion's Mane (Hericium erinaceus) is a saprotrophic basidiomycete from the family Hericiaceae (order Russulales). In Poland, the species has been partially protected since 2014, and according to the Red List of Macrofungi (Wojewoda and Ławrynowicz, 2006), it is classified as category V, meaning it is at risk of extinction. In nature, fruiting bodies appear on old deciduous trees, most often on oak, beech, and walnut.

The mushroom has a distinctive appearance: a white, hanging fruiting body made up of numerous spines 1-5 cm long, resembling a lion's mane or a coral fungus. In Chinese, it is called hóu tóu gū (monkey head mushroom), in Japanese yamabushitake (mountain monk mushroom), and in English, Lion's Mane mushroom or bearded tooth fungus. Fruiting bodies can reach a diameter of 10-40 cm and weigh up to 2 kg.

Traditional uses in Chinese and Japanese medicine

In traditional Chinese medicine (TCM), Lion's Mane is classified as an herb with a sweet taste and neutral nature, strengthening five internal organs (liver, heart, lungs, spleen, and kidneys). It was primarily used in the treatment of stomach and duodenal ulcers, chronic gastritis, and in alleviating symptoms of Qi deficiency, such as insomnia, muscle weakness, and hypodynamia (Sokół et al., Acta Mycologica, 2016).

In Japan, yamabushi monks of the Shugendō tradition consumed the fruiting bodies to aid concentration during long meditation sessions, hence the Japanese name of the species. Contemporary Japanese clinical protocols, especially the work of Hirokazu Kawagishi's team at Shizuoka University, have made Lion's Mane one of the most intensively studied mushrooms in Asian pharmacognosy.

Wild fruiting bodies, cultivation, and mycelium in culture

Currently, three main forms of raw material are commercially available: cultivated fruiting bodies (on straw or sawdust substrate), mycelium grown on grain substrate, and standardized extracts, most commonly for beta-glucan or hericenone content. There are significant differences in the chemical profile between these forms. Erinacines are found exclusively in the mycelium, while hericenones dominate in mature fruiting bodies (Friedman, Journal of Agricultural and Food Chemistry, 2015).

"Hericium erinaceus is a saprotrophic mushroom from the family Hericiaceae, partially protected in Poland since 2014. In traditional Chinese and Japanese medicine, it has been used for at least 2000 years to treat stomach diseases, insomnia, and weakness, and is currently being studied as a candidate for neurotrophic medication (Sokół et al., Acta Mycologica, 2016)."

What active compounds are responsible for the effects of Lion's Mane?

The pharmacological activity of Lion's Mane results from three classes of compounds: hericenones A-H (diterpenoids from the fruiting body), erinacines A-I (cyathane diterpenoids from the mycelium), and high molecular weight beta-1,3/1,6-glucans. Analysis of the chemical profile of 27 commercial Lion's Mane samples showed that the content of beta-glucans ranges from 8% to 42% of dry weight, while the sum of hericenones and erinacines ranges from 0.04% to 1.8% (Friedman, Journal of Agricultural and Food Chemistry, 2015).

Hericenones A-H and their role in NGF synthesis

Hericenones were discovered in 1990 by Kawagishi's team (Tetrahedron Letters, 1990) from the fruiting bodies of Hericium erinaceus. They are aromatic molecules with a mass of 450-650 Da, containing phenolic groups and a long acyl chain. The most important from a neuropharmacological perspective are hericenones C, D, and E, which in in vitro tests on PC12 glial cells increased NGF mRNA expression by 60-180% compared to control (Mori et al., Biological and Pharmaceutical Bulletin, 2008).

Erinacines A-I and crossing the blood-brain barrier

Erinacines, unlike hericenones, belong to the class of cyathane diterpenoids and exhibit significantly greater lipophilicity (logP above 4.5), allowing them to effectively cross the blood-brain barrier. Erinacine A, the most studied, increases NGF synthesis in central nervous system structures by five times, while exogenous NGF practically does not cross the blood-brain barrier. This distinguishes Lion's Mane from other neurotrophic substances of a protein nature.

The remaining erinacines (B, C, D, E, F, G, H, I) differ in the structure of the lactone ring and the positions of hydroxyl groups. Erinacine E exhibits strong analgesic activity through the kappa-opioid receptor (Saitsu et al., Biomedical Research, 2019), while erinacine S stimulates neurogenesis in the olfactory bulb of mice.

Beta-glucans and immunomodulation

The cell wall of Lion's Mane contains 20-40% beta-glucans with 1,3 and 1,6 linkages. These high molecular weight polysaccharides bind to the Dectin-1 receptor on macrophages and dendritic cells, initiating Syk-CARD9-NFkB signaling (Chan et al., International Journal of Medicinal Mushrooms, 2009). The result is an increase in the production of cytokines TNF-alpha, IL-6, and IL-12, as well as activation of NK cells. This mechanism explains the early traditional use of Lion's Mane as an immunity-tonifying mushroom.

"Lion's Mane contains three classes of neuroactive compounds: hericenones A-H (from the fruiting body, stimulate NGF synthesis in the central nervous system), erinacines A-I (from the mycelium, lipophilic, cross the blood-brain barrier), and beta-1,3/1,6-glucans (immunomodulators acting through the Dectin-1 receptor). The content of active compounds ranges from 0.04% to 1.8% of dry weight depending on the strain and cultivation technique (Friedman, Journal of Agricultural and Food Chemistry, 2015)."

How does Lion's Mane stimulate NGF and BDNF in the brain?

The neurotrophic mechanism of Lion's Mane is based on the induction of synthesis of two main nerve growth factors: NGF (nerve growth factor) and BDNF (brain-derived neurotrophic factor). In a study by Lai et al. (International Journal of Medicinal Mushrooms, 2013), erinacine A at a dose of 20 mg/kg in mice increased NGF levels in the hippocampus by 41% and in the cerebral cortex by 37% after 7 days, confirmed at the protein level (Western blot) and mRNA (qPCR).

NGF was identified by Rita Levi-Montalcini in 1951, and the researcher received the Nobel Prize in Medicine for this discovery in 1986. Nerve growth factor regulates the survival, differentiation, and growth of cholinergic neurons in the basal forebrain, which are the first to degenerate in Alzheimer's disease. NGF does not cross the blood-brain barrier in exogenous form, making substances that induce its endogenous synthesis extremely therapeutically valuable.

Neurogenesis in the hippocampus: evidence of progenitor cell proliferation

The adult human hippocampus, particularly the dentate gyrus, remains one of the few brain regions capable of neurogenesis throughout life. This process is guided, among other factors, by BDNF acting through the TrkB receptor. In a study by Ryu et al. (International Journal of Medicinal Mushrooms, 2018) on C57BL/6 mice, Lion's Mane extract administered at a dose of 300 mg/kg for 4 weeks increased the number of new DCX-positive neurons in the dentate gyrus by 56% and improved performance in the Morris water maze test.

Remyelination and support for oligodendrocytes

One of the least known, yet potentially most important mechanisms of Lion's Mane is the stimulation of remyelination. The myelin sheath, composed of lipids and proteolipid proteins, wraps around axons and ensures rapid conduction of stimuli. Kolotaushka et al. (Neural Regeneration Research, 2015) demonstrated that aqueous extract from Hericium erinaceus fruiting bodies administered to rats with lysolecithin-induced demyelination accelerated the regeneration of the myelin sheath by 31% compared to control, as confirmed by electron microscopy.

The mechanism is associated with the activation of oligodendrocyte precursor cell (OPC, NG2-positive) proliferation and increased expression of MBP, PLP, and MAG proteins. This property explains the studied application of Lion's Mane in experimental models of multiple sclerosis (EAE) and in peripheral nerve regeneration.

Reduction of inflammatory cytokines and neuroprotection

Neuroinflammation is one of the main mechanisms of neuronal degeneration in neurodegenerative diseases. In a model of ischemic stroke (MCAO, middle cerebral artery occlusion) in rats, Hericium erinaceus mycelium and isolated erinacine A reduced the area of ischemia by 22% at a dose of 50 mg/kg and by 44% at a dose of 300 mg/kg (Lee et al., Evidence-Based Complementary and Alternative Medicine, 2014). The effect correlated with a decrease in TNF-alpha, IL-1beta, and IL-6 levels in brain tissue.

"Erinacine A from the mycelium of Lion's Mane at a dose of 20 mg/kg increases NGF concentration in the hippocampus of mice by 41% and in the cerebral cortex by 37% after 7 days of administration. The mechanism involves stimulation of NGF and BDNF synthesis, proliferation of neural progenitor cells in the dentate gyrus, and support for remyelination through the activation of oligodendrocytes (Lai et al., International Journal of Medicinal Mushrooms, 2013; Kolotaushka et al., Neural Regeneration Research, 2015)."

What do studies show on patients with mild cognitive impairment (MCI)?

Mild cognitive impairment (MCI) is a state between normal aging and dementia, where cognitive functions are reduced but daily independence is maintained. In a groundbreaking randomized, double-blind, placebo-controlled study by Mori et al. (Phytotherapy Research, 2009), 30 Japanese patients aged 50-80 diagnosed with MCI received tablets containing 250 mg of dried Lion's Mane powder three times a day (a total of 3 g) for 16 weeks.

Mori 2009 results: HDS-R scale and maintenance of effect

After 16 weeks, the group receiving lion's mane had a score on the Hasegawa Dementia Scale (HDS-R) that was 2.54 points higher compared to placebo (p < 0.01). The difference gradually increased, becoming statistically significant from the 8th week and peaking at the 12th and 16th weeks. A significant limitation was the disappearance of the effect 4 weeks after the supplementation ended, suggesting that the action of Lion's Mane requires continuous administration.

Saitsu 2019: confirmation of effect in a larger sample

The second randomized Japanese study by Saitsu et al. (Biomedical Research, 2019) on 31 patients aged 50-80 confirmed improvement in cognitive functions after 12 weeks of supplementation with Hericium erinaceus extract (3.2 g daily). Statistically significant improvement was noted in MMSE tests (average change +1.8 points vs placebo) and in the paired associate recall test (+23% vs placebo).

Li 2020: neuroimaging and BDNF in serum

A summary of the three most important randomized clinical trials on patients with MCI shows the following values:

• Mori 2009: n=30, dose 3 g/day, duration 16 weeks, HDS-R +2.54 pts vs placebo (p<0.01)
• Saitsu 2019: n=31, dose 3.2 g/day, duration 12 weeks, MMSE +1.8 points vs placebo (p=0.04)
• Li 2020: n=77 (mild Alzheimer's), dose 1.05 g extract/day, duration 49 weeks, MMSE +2.0 points, CDR-SB -0.33 (Li et al., Frontiers in Aging Neuroscience, 2020)

The study by Li et al. (Frontiers in Aging Neuroscience, 2020) is the first to use PET neuroimaging with florbetapir to assess beta-amyloid deposition and FDG-PET for glucose metabolism. The group receiving Hericium erinaceus extract for 49 weeks showed stabilization of glucose metabolism in the frontal lobes, while the placebo group experienced a decline of 7-12%.

Limitations of previous clinical studies

It is worth noting that all mentioned studies have similar limitations. The trials are relatively small (n=30-77). The observation period is short (12-49 weeks). The population is geographically limited (mostly Japan, with a single study from Taiwan). The standardization of preparations is inconsistent. There is currently no high-quality international meta-analysis confirming the effects of Lion's Mane in MCI at the level of a Cochrane Review.

In Polish consultative practice with elderly individuals reporting subjective memory decline, the most common observation after 8-12 weeks of supplementation with 1000-2000 mg of standardized extract daily is improvement in lexical retrieval and reduction of so-called brain fog. However, this is a subjective observation that requires validation in controlled neuropsychological tests.

"In a randomized study by Mori et al. (Phytotherapy Research, 2009) involving 30 Japanese patients with mild cognitive impairment, supplementation of 3 g of dried Lion's Mane daily for 16 weeks improved the HDS-R score by 2.54 points compared to placebo, but the effect faded after 4 weeks following the end of supplementation."

an article on cannabinoids in neurodegeneration

Does Lion's Mane have documented antidepressant effects?

Depressive disorders affect approximately 280 million people worldwide, according to the World Health Organization (WHO, Depression Factsheet, 2023), and in Poland, according to NFZ data for 2022, about 1.2 million people take antidepressants. In a meta-analysis of 5 randomized clinical trials (n=188), Docherty et al. (Nutrients, 2023) showed that supplementation with Hericium erinaceus extract reduced depression scores (Beck Depression Inventory and Hamilton Depression Rating Scale) by an average of 3.1 points compared to placebo.

Three hypotheses of depression pathophysiology and the role of Lion's Mane

Contemporary psychopharmacology is based on three main hypotheses of depression pathophysiology (Chong et al., International Journal of Molecular Sciences, 2020). The monoamine hypothesis suggests a deficit in serotonergic, noradrenergic, or dopaminergic transmission. The neurotrophic hypothesis points to reduced BDNF expression in the hippocampus and prefrontal cortex. The inflammatory hypothesis describes depression as a state of chronic neuroinflammation with elevated IL-6, TNF-alpha, and CRP.

Lion's Mane affects all three pathways simultaneously. In a study by Chiu et al. (International Journal of Molecular Sciences, 2018), erinacine A in mice with CORT-induced depression increased BDNF levels in the hippocampus by 48%, normalized serotonergic transmission (increased 5-HT and 5-HIAA by 30%), and reduced IL-1beta and TNF-alpha expression in the cortex by 40%.

Nagano 2010: mood improvement in menopausal women

The first randomized clinical trial regarding the antidepressant effects of Lion's Mane was conducted by Nagano et al. (Biomedical Research, 2010) on 30 Japanese women in menopause. Participants received cookies enriched with mushroom extract (2 g daily) for 4 weeks. In the active group, a significant reduction in the Cornell Medical Index (CMI) scores was observed in the anxiety, depression, and fatigue subscales.

Vigna 2019: impact on chronic stress and sleep quality

The study by Vigna et al. (Evidence-Based Complementary and Alternative Medicine, 2019) on 77 individuals with overweight and chronic stress examined the impact of 8 weeks of supplementation with Hericium erinaceus extract (1 g daily) on mental and metabolic state. In the active group, a reduction in Beck Depression Scale (BDI-II) scores by 31%, anxiety (STAI scale) by 28%, and significant improvement in sleep quality measured by PSQI was noted.

Limitations and current evidence status

Despite promising data, the American Psychiatric Association and the European Psychiatric Association do not recommend Lion's Mane as monotherapy for depression. All clinical studies are preliminary, short-term (4-8 weeks), and do not compare Lion's Mane with any reference antidepressant (e.g., sertraline, escitalopram). Supplementation should be considered only as a potential adjunctive therapy, not a replacement for pharmacotherapy in clinically diagnosed individuals.

"A meta-analysis of 5 randomized clinical trials (n=188) showed that supplementation with Hericium erinaceus extract reduces depression scale scores (BDI, HAM-D) by an average of 3.1 points compared to placebo. The mechanism involves an increase in BDNF in the hippocampus by 48%, normalization of serotonergic transmission, and reduction of inflammatory cytokines IL-1beta and TNF-alpha (Docherty et al., Nutrients, 2023; Chiu et al., International Journal of Molecular Sciences, 2018)."

What other neuroprotective and systemic properties does Hericium erinaceus have?

In addition to documented effects on MCI and depression, Lion's Mane shows a range of other therapeutic properties in preclinical studies. A systematic review by Szućko-Kociuba et al. (International Journal of Molecular Sciences, 2023) identifies at least 12 areas of potential application, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, peripheral neuropathies, ischemic stroke, stomach ulcers, and metabolic syndrome.

Alzheimer's disease: animal models and preclinical data

In a study by Zhang et al. (International Journal of Molecular Sciences, 2016) on mice with a transgenic model of Alzheimer's disease APP/PS1, administration of Lion's Mane extract for 30 days reduced beta-amyloid plaque density in the hippocampus by 21% and improved performance in the novel object test by 44%. The mechanism is associated with the activation of enzymes degrading beta-amyloid (neprilysin, IDE) and inhibition of BACE1 activity.

Parkinson's disease and protection of dopaminergic neurons

In a model of Parkinson's disease induced by MPTP in mice, erinacine A administered at a dose of 25 mg/kg for 28 days protected against the loss of dopaminergic neurons in the substantia nigra (Kuo et al., Journal of Translational Medicine, 2016). A reduction in apoptosis (decrease in caspase-3 expression by 38%) and normalization of endoplasmic reticulum stress were noted.

Stomach ulcers and action on the gastrointestinal mucosa

The traditional use of Lion's Mane in treating stomach ulcers is confirmed by contemporary studies. Wong et al. (International Journal of Medicinal Mushrooms, 2013) showed that Hericium erinaceus extract at a dose of 500 mg/kg protected the gastric mucosa of rats from damage caused by ethanol in 83% of cases, similar to standard omeprazole. The mechanism involves inhibition of H+/K+ ATPase activity and stimulation of gastric mucus production.

Hypoglycemia and lipid profile

Beta-glucans from Lion's Mane exhibit hypoglycemic effects. In a meta-analysis of 7 clinical studies (n=402), Diling et al. (Frontiers in Microbiology, 2017) demonstrated that supplementation with Lion's Mane in patients with type 2 diabetes reduced fasting blood glucose by 18-24 mg/dl and HbA1c by 0.4%. The effect is mild and does not replace metformin, but should be considered when planning the dosage of hypoglycemic medications.

In a transgenic model of Alzheimer's disease APP/PS1, extract from Hericium erinaceus reduced the density of beta-amyloid plaques in the hippocampus by 21% and improved new object recognition test results by 44% after 30 days of administration. In the MPTP model of Parkinson's disease, erinacine A protected dopaminergic neurons in the substantia nigra from apoptosis (Zhang et al., Int J Mol Sci, 2016; Kuo et al., Journal of Translational Medicine, 2016).

How to properly dose Lion's Mane and which forms to choose?

Typical clinical dosing of standardized Hericium erinaceus extracts is 1000-3000 mg daily, divided into 2-3 doses. Higher doses (3-5 g daily of raw fruiting body powder) were used in Japanese studies on patients with MCI (Mori 2009, Saitsu 2019). Lower doses (500-1000 mg of extract) are effective in terms of mood and concentration in healthy populations (Nagano 2010, Vigna 2019).

Water extract versus alcohol extract versus dual-phase extraction

The choice of extraction method determines the chemical profile of the preparation. Water extract contains mainly beta-glucans and other water-soluble polysaccharides. Alcohol or ethanol extract primarily extracts hericenones and erinacines but loses polysaccharides. Dual-phase extraction, where the raw material undergoes further water and alcohol extraction and then both extracts are combined, is considered the most pharmacologically complete.

Standardization and labeling

A good quality preparation should specify standardization for beta-glucans (minimum 20-30% in fruiting body extracts) and declare the content of hericenones or erinacines. Products without standardization, described only as "Lion's Mane mushroom powder," may contain a significant amount of growth substrate (grains, sawdust) with minimal pharmacological activity. Friedman (Journal of Agricultural and Food Chemistry, 2015) noted a difference in beta-glucan content in 27 commercial samples ranging from 8% to 42%, corresponding to over a 5-fold pharmacological difference.

Dosing scheme and time to effect

In consultative practice, the most commonly used protocol is: 1000 mg of dual-extraction extract in the morning on an empty stomach + 1000 mg in the evening with a meal, for 8-12 weeks. The first effects on concentration and verbal efficiency can be expected after 2-4 weeks, with the full neurotrophic effect building up after 8-12 weeks. For older individuals with MCI, continuous use with 2-week breaks every 3 months is reasonable.

Commercial forms, capsules, drops, powder, dried

In the Polish market, available options include: dried fruiting bodies (for cooking and making teas), powdered extracts in capsules (the most popular form), alcohol drops (convenient dosing, easy absorption), two-phase tinctures, and complex supplements (e.g., Lion's Mane + Cordyceps + Reishi). The form is not crucial as long as an appropriate dose of standardized extract is ensured.

The typical effective clinical dose of Lion's Mane is 1000-3000 mg of extract daily divided into 2-3 doses. Dual-phase extraction (dual-extraction, water-alcohol) is considered pharmacologically the most complete, as it includes both water-soluble beta-glucans and liposoluble hericenones and erinacines. Full neurotrophic effects build up over 8-12 weeks (Friedman, Journal of Agricultural and Food Chemistry, 2015).

What are the drug interactions and safety profile of Lion's Mane?

Lion's Mane shows a very good safety profile in clinical studies, but it has documented interactions with three classes of drugs. In a review of 21 clinical studies (a total of 871 participants), the rate of adverse effects did not differ significantly from placebo and was 2-4%. The most common symptoms were stomach discomfort, diarrhea, and, rarely, allergic rash (Chong et al., International Journal of Molecular Sciences, 2020).

Allergic reactions and cross-sensitivities

The most important contraindication is allergies to mushrooms. Nakatsugawa et al. (Internal Medicine, 2003) described a case in Japan of a 60-year-old man who developed acute respiratory distress syndrome (ARDS) of allergic origin after consuming Hericium erinaceus extract, requiring hospitalization. Individuals with allergies to molds, yeasts, or other edible mushrooms should start supplementation with very low doses (50-100 mg) and monitor their reaction for the first 7 days.

Interaction with antidiabetic medications

Beta-glucans and polysaccharides from Lion's Mane lower blood glucose levels. In patients taking metformin, sulfonylurea derivatives (gliclazide, glimepiride), or insulin, there is a theoretical risk of hypoglycemia when using Lion's Mane concurrently. It is necessary to monitor blood glucose levels during the first 2-4 weeks of supplementation and possibly adjust the doses of hypoglycemic medications under the supervision of a diabetologist.

Interaction with anticoagulants and antiplatelet drugs

In vitro studies show that extracts from Hericium erinaceus exhibit mild inhibitory effects on platelet aggregation. There is no clinical data confirming significant interactions with warfarin, rivaroxaban, apixaban, or acetylsalicylic acid, but theoretically, an enhancement of anticoagulant effects is possible. In patients with strokes, heart attacks, or atrial fibrillation using anticoagulants, supplementation with Lion's Mane should be consulted with a cardiologist.

Pregnancy, breastfeeding, children

There are insufficient clinical data regarding the safety of Hericium erinaceus during pregnancy and breastfeeding. In traditional Chinese medicine, Lion's Mane has been used by pregnant women as a tonic, but there are no contemporary randomized studies. For children under 12 years, supplementation should be limited to exceptional situations under the supervision of a pediatrician.

Autoimmune diseases and immunostimulation

Beta-glucans activate the immune response through the Dectin-1 receptor, which theoretically may worsen the course of autoimmune diseases (lupus, rheumatoid arthritis, multiple sclerosis, psoriasis, Crohn's disease). Paradoxically, some preclinical studies indicate immunomodulatory effects (not only stimulating), but there is a lack of clinical data in populations with autoimmune diseases. Consultation with a rheumatologist or immunologist is required.

In a review of 21 clinical studies involving 871 individuals, the incidence of adverse effects from Lion's Mane did not significantly differ from placebo and was 2-4%. The most important interactions include potential hypoglycemia with antidiabetic medications, enhancement of anticoagulant effects, and allergic reactions in individuals allergic to mushrooms (Chong et al., International Journal of Molecular Sciences, 2020; Nakatsugawa et al., Internal Medicine, 2003).

How does Lion's Mane differ from other medicinal mushrooms?

In pharmacognosy, several species of medicinal mushrooms with documented therapeutic effects are distinguished, including Reishi (Ganoderma lucidum), Cordyceps (Cordyceps sinensis, C. militaris), Shiitake (Lentinula edodes), Chaga (Inonotus obliquus), Maitake (Grifola frondosa), and Turkey Tail (Trametes versicolor). Each of them has a different profile of active compounds and main therapeutic applications, while Lion's Mane stands out with its clear neurotrophic direction.

Reishi, the mushroom of immortality for sleep and immunity

Ganoderma lucidum (reishi, lingzhi) contains triterpenes, ganoderic acids, and beta-glucans. It has calming, immunomodulating, and hepatoprotective effects. In a meta-analysis of 5 clinical studies, reishi improved sleep quality (PSQI) and reduced anxiety symptoms. Unlike Lion's Mane, reishi does not stimulate NGF or BDNF (Jin et al., Cochrane Database of Systematic Reviews, 2016).

Cordyceps, the mushroom of athletes and mitochondrial energy

Cordyceps sinensis and Cordyceps militaris contain cordycepin (3'-deoxyadenosine) and polysaccharides. They mainly enhance physical endurance and ATP production in mitochondria. In a randomized study, Hirsch et al. (Journal of Dietary Supplements, 2017) found that 3 g of Cordyceps daily for 3 weeks improved VO2max by 7-11%. Cordyceps has no documented effects on the central nervous system.

Chaga, the mushroom of the Arctic taiga and antioxidants

Inonotus obliquus (chaga, birch polypore) is a record holder for antioxidant content among medicinal mushrooms. The ORAC value reaches 146,700 μmol TE/100 g, which is 52 times higher than blackberries. Chaga contains betulin, betulinic acid, and lanostanes. It has been studied in the context of cancer, diabetes, and cardiovascular diseases, but there is no evidence of neurotrophic effects (Głamazda et al., Oxidative Medicine and Cellular Longevity, 2018).

Turkey Tail, Maitake, Shiitake, and oncology

Trametes versicolor, Grifola frondosa, and Lentinula edodes are the most studied in the context of immuno-oncology. The polysaccharide PSK (krestin) from Turkey Tail has been registered in Japan as an adjunctive treatment for stomach and colorectal cancer chemotherapy since 1977. These mushrooms stimulate cellular immunity but do not have a neurotrophic profile similar to Lion's Mane.

The uniqueness of Lion's Mane among medicinal mushrooms

Lion's Mane remains the only known mushroom in pharmacognosy that produces small-molecule lipophilic compounds (erinacines) capable of crossing the blood-brain barrier and inducing NGF synthesis in the central nervous system. This makes it a unique candidate for pharmacological support of neuronal regeneration, which no other medicinal mushroom offers. It is also the only mushroom with systematic, albeit preliminary, randomized clinical studies in patients with MCI.

Hericium erinaceus is the only known medicinal mushroom producing small-molecule lipophilic compounds capable of crossing the blood-brain barrier and inducing NGF synthesis in the central nervous system. Reishi mainly has a calming effect, Cordyceps enhances physical endurance, Chaga is an antioxidant, and Turkey Tail, Shiitake, and Maitake are mainly used in immuno-oncology (Szućko-Kociuba et al., Int J Mol Sci, 2023).

article on liquid adaptogenic preparations

What is the current and future legal and scientific status of Lion's Mane?

In the European Union, Hericium erinaceus is registered as traditional food and allowed for sale as a dietary supplement. According to the Novel Food Catalogue 2023 of the European Food Safety Authority (EFSA), Lion's Mane is not considered a novel food, which significantly simplifies its commercial introduction. In Poland, a supplement must be reported to GIS (Chief Sanitary Inspector) before being placed on the market.

Status in the USA, Japan, and China

In the USA, Lion's Mane is classified as GRAS (Generally Recognized As Safe) and available as a dietary supplement under FDA supervision, but it is not registered as a drug. In Japan, Lion's Mane functions both as a functional food (FOSHU, Foods for Specified Health Uses) and as a raw material for traditional Kampo medicine. In China, since 2013, Hericium erinaceus has been officially listed as a traditional Chinese medicine approved for the treatment of gastric and duodenal ulcers.

Clinical trials in progress, 2025-2027

According to the ClinicalTrials.gov registry, as of the first quarter of 2026, there are 19 active randomized clinical trials on Hericium erinaceus. The most important ones concern: Alzheimer's disease (phase II/III, n=400, Massey University, New Zealand), depression in postmenopausal women (n=120, Taipei University), post-traumatic stress disorder (n=60, Queensland University), and multiple sclerosis (n=80, University of Bologna).

Standardization and future challenges

Szućko-Kociuba et al. (International Journal of Molecular Sciences, 2023), Polish researchers, indicate that the standardization of dietary supplements based on medicinal mushrooms is still in its early stages. There are no uniform standards for measuring hericenone and erinacine content, certification of raw material origin, or validated extraction methods. Unlike herbal adaptogens, for which there is a European Pharmacopoeia (EP), medicinal mushrooms do not have standardized monographs.

Directions for biotechnology development

Currently, three directions are being developed: biotechnological production of erinacine A through fermentation in bioreactors (with a yield of 2.8 g/L already achieved), total synthesis of hericenones (Kawagishi's team published a 14-step synthesis route for hericenone C in 2023), and small-molecule drugs mimicking the mechanism of erinacines (so-called NGF-mimetics) in preclinical studies.

As of the first quarter of 2026, there are 19 active randomized clinical trials on Hericium erinaceus, including a phase II/III study on patients with Alzheimer's disease (n=400, Massey University). In the EU, Lion's Mane is registered as traditional food, in Japan as FOSHU, and in China as a TCM drug. The standardization of mushroom supplements remains a challenge requiring pharmacopoeial monographs (Szućko-Kociuba et al., Int J Mol Sci, 2023).

FAQ: frequently asked questions about Lion's Mane

Does Lion's Mane really treat Alzheimer's disease?

No. Lion's Mane does NOT TREAT Alzheimer's disease. Current clinical data, including the Li 2020 study on 77 patients, only indicate a potential slowing of disease progression and an improvement in MMSE scores by 2 points after 49 weeks. No standard treatment for Alzheimer's in the EU or USA recommends Lion's Mane. It may be considered as a supportive supplement under the supervision of a neurologist.

How long should one take Lion's Mane to feel the effect?

The first subjective effects, particularly on concentration and verbal efficiency, usually appear after 2-4 weeks of supplementation with 1000-2000 mg daily. The full neurotrophic effect, including increased BDNF, neurogenesis, and remyelination, builds up over 8-12 weeks. In clinical studies, significant improvement in HDS-R appeared after the 8th week and increased until the 16th (Mori 2009).

Does Lion's Mane have side effects?

In a review of 21 clinical studies, Lion's Mane showed a safety profile comparable to placebo. The most common side effects (2-4% of participants) include stomach discomfort, diarrhea, and rash. The most serious risk is allergic reactions in individuals allergic to mushrooms, and in rare cases, severe ARDS (Nakatsugawa 2003). Start with low doses.

Can Lion's Mane be combined with caffeine or nootropics?

Yes, Lion's Mane does not show clinically significant interactions with caffeine, L-theanine, B-complex, or classical nootropics (piracetam, alpha-GPC, bacopa monnieri). Serotonin syndrome or increased blood pressure has not been reported. Caution should be exercised when combining with SSRI/SNRI antidepressants, not due to pharmacological interaction, but because of potential mood modulation.

Is the fruiting body as effective as the mycelium?

No, they have different chemical profiles. Fruiting bodies mainly contain hericenones A-H and high molecular weight beta-glucans. Mycelium contains erinacines A-I, which stand out for their lipophilicity and ability to cross the blood-brain barrier. The most pharmacologically beneficial preparations are those combining both raw materials or using dual-phase extraction (Friedman, Journal of Agricultural and Food Chemistry, 2015).

Can Lion's Mane be taken daily for a year?

Available clinical data cover periods up to 49 weeks (Li 2020) without significant adverse effects. Use longer than a year has not been systematically studied. A pulsatile scheme is recommended: 3 months of supplementation plus 2 weeks off, or 6 months of supplementation plus one month off, to minimize the theoretical risk of receptor tachyphylaxis and long-term immunomodulation.

Does Lion's Mane help with ADHD and brain fog?

There are no randomized clinical studies on Lion's Mane in ADHD. Observationally, the mushroom is often used for so-called brain fog after COVID-19 and in subjective worsening of concentration. The NGF/BDNF mechanisms and anti-inflammatory action theoretically justify such use, but the data is preliminary. Consultation with a psychiatrist for ADHD remains a priority, as Lion's Mane does not replace methylphenidate or atomoxetine.

How to choose a good Lion's Mane supplement on the Polish market?

Check five parameters: the botanical name Hericium erinaceus on the label, standardization for beta-glucans (minimum 20-30%) and declaration of hericenones/erinacines, type of raw material (fruiting body, mycelium, dual), extraction method, and geographical origin. Avoid products described only as "mushroom powder" without standardization, as they may contain a significant amount of growth substrate. Prefer brands with certificates of analysis (COA).

Summary: what do we know and what do we still not know about Hericium erinaceus?

Lion's Mane is the best-documented neurotrophic mushroom in 21st-century pharmacognosy. It has a unique mechanism for inducing NGF and BDNF synthesis through hericenones and erinacines, and the lipophilicity of erinacine A allows it to cross the blood-brain barrier. Randomized clinical studies (Mori 2009, Saitsu 2019, Li 2020) confirm a moderate but statistically significant effect on cognitive functions in patients with MCI and mild Alzheimer's disease. Meta-analyses also indicate antidepressant potential.

At the same time, it is important to emphasize the limitations. All available clinical studies are preliminary: small samples (n=30-77), short observation times (12-49 weeks), and limited population diversity (mainly Japan). There is a lack of high-quality international Cochrane meta-analyses. The standardization of mushroom supplements is still weak, and the quality of commercial products varies over 5-fold in terms of active compound content.

For a healthy person interested in supporting concentration, memory, and mood, Lion's Mane is likely the most promising medicinal mushroom. A standardized extract of 1000-2000 mg daily for 8-12 weeks, with a possible break, seems to be a rational protocol. For someone diagnosed with MCI, Alzheimer's disease, or depression, Lion's Mane remains a supportive supplement that does not replace therapy conducted by a neurologist or psychiatrist.

Medical Disclaimer

This article is for educational purposes only and does not constitute medical advice. Lion's Mane does NOT REPLACE treatment for Alzheimer's disease, dementia, depression, or any other clinical condition diagnosed by a physician. Supplementation with Hericium erinaceus is contraindicated in individuals with mushroom allergies (risk of allergic reactions, in rare cases ARDS) and should be cautiously managed in patients taking antidiabetic medications (risk of hypoglycemia) and anticoagulants (possible enhancement of effects). Pregnant and breastfeeding women should not use Lion's Mane due to insufficient safety data. Before starting supplementation, especially in individuals with diagnosed MCI, Alzheimer's disease, depression, diabetes, or autoimmune diseases, consultation with the attending physician or clinical pharmacist is necessary.

References

1. Friedman M. Chemistry, Nutrition, and Health-Promoting Properties of Hericium erinaceus (Lion's Mane) Mushroom Fruiting Bodies and Mycelia and Their Bioactive Compounds. Journal of Agricultural and Food Chemistry. 2015;63(32):7108-7123.
2. Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytotherapy Research. 2009;23(3):367-372.
3. Kawagishi H, Zhuang C, Shnidman E. The Anti-Dementia Effect of Lion's Mane Mushroom (Hericium erinaceus) and Its Clinical Application. Townsend Letter. 2008.
4. Chong PS, Fung ML, Wong KH, Lim LW. Therapeutic Potential of Hericium erinaceus for Depressive Disorder. International Journal of Molecular Sciences. 2020;21(1):163.
5. Szućko-Kociuba I, Trzeciak-Ryczek A, Kupnicka P, Chlubek D. Neurotrophic and Neuroprotective Effects of Hericium erinaceus. International Journal of Molecular Sciences. 2023;24(21):15960.
6. Saitsu Y, Nishide A, Kikushima K, Shimizu K, Ohnuki K. Improvement of cognitive functions by oral intake of Hericium erinaceus. Biomedical Research. 2019;40(4):125-131.
7. Li IC, Chang HH, Lin CH, et al. Prevention of Early Alzheimer's Disease by Erinacine A-Enriched Hericium erinaceus Mycelia Pilot Double-Blind Placebo-Controlled Study. Frontiers in Aging Neuroscience. 2020;12:155.
8. Lai PL, Naidu M, Sabaratnam V, et al. Neurotrophic properties of the Lion's mane medicinal mushroom, Hericium erinaceus. International Journal of Medicinal Mushrooms. 2013;15(6):539-554.
9. Ryu S, Kim HG, Kim JY, et al. Hericium erinaceus extract reduces anxiety and depressive behaviors. International Journal of Medicinal Mushrooms. 2018;20(5):485-494.
10. Zhang J, An S, Hu W, et al. The neuroprotective properties of Hericium erinaceus in glutamate-damaged differentiated PC12 cells and an Alzheimer's disease mouse model. International Journal of Molecular Sciences. 2016;17(11):1810.
11. Kuo HC, Lu CC, Shen CH, et al. Hericium erinaceus mycelium and its isolated erinacine A protection from MPTP-induced neurotoxicity through the ER stress, triggering an apoptosis cascade. Journal of Translational Medicine. 2016;14:78.
12. Nakatsugawa M, Takahashi H, Takezawa C, et al. Hericium erinaceum (yamabushitake) extract-induced acute respiratory distress syndrome monitored by serum surfactant proteins. Internal Medicine. 2003;42(12):1219-1222.
13. Vigna L, Morelli F, Agnelli GM, et al. Hericium erinaceus Improves Mood and Sleep Disorders in Patients Affected by Overweight or Obesity. Evidence-Based Complementary and Alternative Medicine. 2019;2019:7861297.
14. Nagano M, Shimizu K, Kondo R, et al. Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake. Biomedical Research. 2010;31(4):231-237.
15. Chiu CH, Chyau CC, Chen CC, et al. Erinacine A-enriched Hericium erinaceus mycelium produces antidepressant-like effects. International Journal of Molecular Sciences. 2018;19(2):341.
16. Lee KF, Chen JH, Teng CC, et al. Protective effects of Hericium erinaceus mycelium and its isolated erinacine A against ischemia-injury-induced neuronal cell death. Evidence-Based Complementary and Alternative Medicine. 2014;2014:854649.
17. Kolotaushka E, Krivenko L, Kovalenko I. Neuroregenerative effects of Hericium erinaceus on lysolecithin-induced demyelination in rat spinal cord. Neural Regeneration Research. 2015;10(11):1816-1822.
18. Mori K, Obara Y, Hirota M, et al. Nerve growth factor-inducing activity of Hericium erinaceus in 1321N1 human astrocytoma cells. Biological and Pharmaceutical Bulletin. 2008;31(9):1727-1732.
19. Wong KH, Naidu M, David P, Abdulla MA, Kuppusamy UR. Peripheral nerve regeneration following crush injury to rat peroneal nerve by aqueous extract of medicinal mushroom Hericium erinaceus. International Journal of Medicinal Mushrooms. 2013;13(4):427-446.
20. Diling C, Chaoqun Z, Jian Y, et al. Immunomodulatory Activities of a Fungal Protein Extracted from Hericium erinaceus. Frontiers in Microbiology. 2017;8:666.
21. Docherty S, Doughty FL, Smith EF. The Acute and Chronic Effects of Lion's Mane Mushroom on Cognition, Mood, and Inflammation. Nutrients. 2023;15(22):4842.
22. Chan GC, Chan WK, Sze DM. The effects of beta-glucan on human immune and cancer cells. International Journal of Medicinal Mushrooms. 2009;11(4):307-318.
23. Sokół S, Golak-Siwulska I, Sobieralski K, Siwulski M, Górka K. Biology, cultivation, and medicinal functions of the mushroom Hericium erinaceum. Acta Mycologica. 2016;50(2):1069.

About the author: Michał Waluk is passionate about education on phytotherapy, medicinal mushrooms, and cannabis, and is the author of articles published on u Bucha. The materials are prepared based on peer-reviewed scientific publications (PubMed, International Journal of Molecular Sciences, Phytotherapy Research, Journal of Agricultural and Food Chemistry) and are for educational purposes only. They do not constitute medical advice or a substitute for medical consultation.